NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 9 – Medication<br />
Pregnant women<br />
Appropriate management of the pregnant woman at risk of, or with diagnosed glaucoma requires a<br />
balance between the treatment’s risk to the foetus and the risk to the mother if treatment is reduced<br />
or suspended.<br />
Pregnancy often alters IOP, which tends to be lower in mid to late term, possibly from hormonal<br />
changes or decreased episcleral venous pressure. This may allow certain patients to be monitored<br />
on reduced medications or without treatment during pregnancy (SEAGIG 2003). Some health care<br />
providers and patients opt for wide margins of safety, avoiding the use of medication for early<br />
or mild disease when the risk of significant glaucomatous progression during the course of the<br />
pregnancy is small.<br />
As many pregnancies are unplanned, exposure to medication typically occurs before women know<br />
they are pregnant. While no glaucoma medications are known to be human teratogens, none<br />
have been proven to be completely risk-free either. Therefore, when prescribing medications for<br />
pregnant women or women planning a pregnancy, careful consideration of the risks and benefits<br />
of treatment is important. Table 9.8 provides a summary of medication use for the treatment of<br />
glaucoma during pregnancy. A summary of the Australian Drug Evaluation Committee (ADEC)<br />
Pregnancy Categories is also provided to assist decision-making. There are case reports of the safe<br />
and effective use of all anti-glaucoma medications during pregnancy. However the data are often<br />
limited and as such, general caution over the use of all anti-glaucoma medications is recommended.<br />
Health care providers may consider contacting a specialist pregnancy drug information centre to<br />
discuss the optimal glaucoma management of pregnant patients.<br />
In some situations, glaucoma during pregnancy may be best managed through surgery, however,<br />
this management path is not without its risks. The additional risks associated with glaucoma<br />
surgery in pregnant patients include the use of local anaesthetics, post-operative medications,<br />
gastro-oesophageal reflux and its associated complications and an increased risk of aortic and<br />
vena cava compression by the uterus in the 2nd and 3rd trimesters due to supine positioning.<br />
For these reasons laser therapy may be considered first as it offers significant advantages over<br />
surgical management of glaucoma during pregnancy. These include the use of only topical<br />
anaesthesia, upright positioning during procedure, faster rehabilitation, and reduced need for<br />
post-operative medications both in dosage and duration (Chung, Kwok & Chung 2004).<br />
The Australian categorisation of risk of drug use during pregnancy comprises the following<br />
categories:<br />
Category A: Drugs which have been taken by a large number of pregnant women and women of<br />
childbearing age without any proven increase in the frequency of malformations or other direct or<br />
indirect harmful effects on the foetus.<br />
Category C: Drugs which, owing to their pharmacological effects, have caused or may be<br />
suspected of causing, harmful effects on the human foetus or neonate without causing<br />
malformations. These effects may be reversible.<br />
Category B1: Drugs which have been taken by only a limited number of pregnant women and<br />
women of childbearing age, without an observed increase in the frequency of malformation or<br />
other direct or indirect harmful effects in the human foetus. Studies in animals have not shown<br />
evidence of an increased occurrence of foetal damage.<br />
Category B2: Drugs which have been taken by only a limited number of pregnant women and<br />
women of childbearing age, without an observed increase in the frequency of malformation or<br />
other direct or indirect harmful effects in the human foetus. Studies in animals are inadequate or<br />
may be lacking, but available data show no evidence of an increased risk of foetal damage.<br />
132 National Health and Medical Research Council